论文信息 - Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomized, phase 3 study to compare the efficacy and safety of cisplatin plus Lipusu (LP) versus cisplatin plus gemcitabine (GP) as first‐line treatment in locally advanced or metastatic LSCC.

[1] N. Yang,et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer , 2021, JAMA oncology.

[2] I. Melero,et al. Paradigms on Immunotherapy Combinations with Chemotherapy. , 2021, Cancer discovery.

[3] A. Luster,et al. Chemokines and the immune response to cancer. , 2021, Immunity.

[4] P. Hegde,et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[5] Hongyu Zhao,et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[6] T. Choueiri,et al. IL-8 and cancer prognosis on immunotherapy , 2020, Nature Medicine.

[7] Guanxiong Zhang,et al. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8] M. Socinski,et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9] L. Shen,et al. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer , 2019, JAMA network open.

[10] D. Butkiewicz,et al. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer , 2019, BMC Cancer.

[11] Ying Cheng,et al. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). , 2019, European journal of cancer.

[12] I. Melero,et al. Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[13] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14] Xiaozhen Liu,et al. Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer. , 2018, Lung cancer.

[15] L. Sheng,et al. Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma , 2018, Cancer Chemotherapy and Pharmacology.

[16] R. Halaban,et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17] L. Horn,et al. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18] M. Socinski,et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19] C. Schumann,et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[20] Jiandong Wang,et al. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry , 2014, Journal of experimental & clinical cancer research : CR.

[21] Nikolaos Koufos,et al. Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[22] L. Bracci,et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[23] B. Lippitz,et al. Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.

[24] Qian Zhang,et al. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25] Susanna M Cramb,et al. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[27] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[28] K. E. Briggs,et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. , 1998, International journal of oncology.

[29] A. Janoff,et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts , 1997, International journal of cancer.

[30] R. Straubinger,et al. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. , 1996, Cancer letters.

[31] R. Straubinger,et al. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. , 1993, Cancer research.

[32] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[34] R. Straubinger,et al. Novel Taxol formulations: Taxol-containing liposomes. , 1993, Journal of the National Cancer Institute. Monographs.